198 related articles for article (PubMed ID: 35605746)
1. Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer.
Van Baelen K; Geukens T; Maetens M; Tjan-Heijnen V; Lord CJ; Linn S; Bidard FC; Richard F; Yang WW; Steele RE; Pettitt SJ; Van Ongeval C; De Schepper M; Isnaldi E; Nevelsteen I; Smeets A; Punie K; Voorwerk L; Wildiers H; Floris G; Vincent-Salomon A; Derksen PWB; Neven P; Senkus E; Sawyer E; Kok M; Desmedt C
Ann Oncol; 2022 Aug; 33(8):769-785. PubMed ID: 35605746
[TBL] [Abstract][Full Text] [Related]
2. ROSALINE: a phase II, neoadjuvant study targeting ROS1 in combination with endocrine therapy in invasive lobular carcinoma of the breast.
Agostinetto E; Nader-Marta G; Paesmans M; Ameye L; Veys I; Buisseret L; Neven P; Taylor D; Fontaine C; Duhoux FP; Canon JL; Denys H; Coussy F; Chakiba C; Ribeiro JM; Piccart M; Desmedt C; Ignatiadis M; Aftimos P
Future Oncol; 2022 Jul; 18(22):2383-2392. PubMed ID: 35695563
[TBL] [Abstract][Full Text] [Related]
3. ERBB2 mutation is associated with a worse prognosis in patients with CDH1 altered invasive lobular cancer of the breast.
Ping Z; Siegal GP; Harada S; Eltoum IE; Youssef M; Shen T; He J; Huang Y; Chen D; Li Y; Bland KI; Chang HR; Shen D
Oncotarget; 2016 Dec; 7(49):80655-80663. PubMed ID: 27811364
[TBL] [Abstract][Full Text] [Related]
4. St Gallen 2019 guidelines understage the axilla in lobular breast cancer: a population-based study.
Narbe U; Bendahl PO; Fernö M; Ingvar C; Dihge L; Rydén L
Br J Surg; 2021 Dec; 108(12):1465-1473. PubMed ID: 34636842
[TBL] [Abstract][Full Text] [Related]
5. The prognosis of invasive ductal carcinoma, lobular carcinoma and mixed ductal and lobular carcinoma according to molecular subtypes of the breast.
Zhao H
Breast Cancer; 2021 Jan; 28(1):187-195. PubMed ID: 32812198
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive Review of Molecular Mechanisms and Clinical Features of Invasive Lobular Cancer.
Pramod N; Nigam A; Basree M; Mawalkar R; Mehra S; Shinde N; Tozbikian G; Williams N; Majumder S; Ramaswamy B
Oncologist; 2021 Jun; 26(6):e943-e953. PubMed ID: 33641217
[TBL] [Abstract][Full Text] [Related]
7. Effect of histological breast cancer subtypes invasive lobular versus non-special type on survival in early intermediate-to-high-risk breast carcinoma: results from the SUCCESS trials.
Dayan D; Lukac S; Rack B; Ebner F; Fink V; Leinert E; Veselinovic K; Schütze S; El Taie Z; Janni W; Friedl TWP
Breast Cancer Res; 2023 Dec; 25(1):153. PubMed ID: 38098086
[TBL] [Abstract][Full Text] [Related]
8. Canonical Kaiso target genes define a functional signature that associates with breast cancer survival and the invasive lobular carcinoma histological type.
Sijnesael T; Richard F; Rätze MA; Koorman T; Bassey-Archibong B; Rohof C; Daniel J; Desmedt C; Derksen PW
J Pathol; 2023 Dec; 261(4):477-489. PubMed ID: 37737015
[TBL] [Abstract][Full Text] [Related]
9. Novel markers for differentiation of lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysis.
Turashvili G; Bouchal J; Baumforth K; Wei W; Dziechciarkova M; Ehrmann J; Klein J; Fridman E; Skarda J; Srovnal J; Hajduch M; Murray P; Kolar Z
BMC Cancer; 2007 Mar; 7():55. PubMed ID: 17389037
[TBL] [Abstract][Full Text] [Related]
10. E-cadherin immunohistochemical expression in invasive lobular carcinoma of the breast: correlation with morphology and CDH1 somatic alterations.
Grabenstetter A; Mohanty AS; Rana S; Zehir A; Brannon AR; D'Alfonso TM; DeLair DF; Tan LK; Ross DS
Hum Pathol; 2020 Aug; 102():44-53. PubMed ID: 32599083
[TBL] [Abstract][Full Text] [Related]
11. Inter-observer agreement for the histological diagnosis of invasive lobular breast carcinoma.
Christgen M; Kandt LD; Antonopoulos W; Bartels S; Van Bockstal MR; Bredt M; Brito MJ; Christgen H; Colpaert C; Cserni B; Cserni G; Daemmrich ME; Danebrock R; Dedeurwaerdere F; van Deurzen CH; Erber R; Fathke C; Feist H; Fiche M; Gonzalez CA; Ter Hoeve ND; Kooreman L; Krech T; Kristiansen G; Kulka J; Laenger F; Lafos M; Lehmann U; Martin-Martinez MD; Mueller S; Pelz E; Raap M; Ravarino A; Reineke-Plaass T; Schaumann N; Schelfhout AM; De Schepper M; Schlue J; Van de Vijver K; Waelput W; Wellmann A; Graeser M; Gluz O; Kuemmel S; Nitz U; Harbeck N; Desmedt C; Floris G; Derksen PW; van Diest PJ; Vincent-Salomon A; Kreipe H
J Pathol Clin Res; 2022 Mar; 8(2):191-205. PubMed ID: 34889530
[TBL] [Abstract][Full Text] [Related]
12. Loss of function of NF1 is a mechanism of acquired resistance to endocrine therapy in lobular breast cancer.
Sokol ES; Feng YX; Jin DX; Basudan A; Lee AV; Atkinson JM; Chen J; Stephens PJ; Frampton GM; Gupta PB; Ross JS; Chung JH; Oesterreich S; Ali SM; Hartmaier RJ
Ann Oncol; 2019 Jan; 30(1):115-123. PubMed ID: 30423024
[TBL] [Abstract][Full Text] [Related]
13. Relapsed classic E-cadherin (CDH1)-mutated invasive lobular breast cancer shows a high frequency of HER2 (ERBB2) gene mutations.
Ross JS; Wang K; Sheehan CE; Boguniewicz AB; Otto G; Downing SR; Sun J; He J; Curran JA; Ali S; Yelensky R; Lipson D; Palmer G; Miller VA; Stephens PJ
Clin Cancer Res; 2013 May; 19(10):2668-76. PubMed ID: 23575477
[TBL] [Abstract][Full Text] [Related]
14. Invasive lobular breast cancer: the prognostic impact of histopathological grade, E-cadherin and molecular subtypes.
Engstrøm MJ; Opdahl S; Vatten LJ; Haugen OA; Bofin AM
Histopathology; 2015 Feb; 66(3):409-19. PubMed ID: 25283075
[TBL] [Abstract][Full Text] [Related]
15. Low risk of invasive lobular carcinoma of the breast in carriers of BRCA1 (hereditary breast and ovarian cancer) and TP53 (Li-Fraumeni syndrome) germline mutations.
Ditchi Y; Broudin C; El Dakdouki Y; Muller M; Lavaud P; Caron O; Lejri D; Baynes C; Mathieu MC; Salleron J; Benusiglio PR
Breast J; 2019 Jan; 25(1):16-19. PubMed ID: 30414230
[TBL] [Abstract][Full Text] [Related]
16. Strong adverse effect of epidermal growth factor receptor 2 overexpression on prognosis of patients with invasive lobular breast cancer: a comparative study with invasive ductal breast cancer in Chinese population.
Wang T; Ma Y; Wang L; Liu H; Chen M; Niu R
Tumour Biol; 2015 Aug; 36(8):6113-24. PubMed ID: 25804795
[TBL] [Abstract][Full Text] [Related]
17. Nonlobular Invasive Breast Carcinomas with Biallelic Pathogenic CDH1 Somatic Alterations: A Histologic, Immunophenotypic, and Genomic Characterization.
Derakhshan F; Da Cruz Paula A; Selenica P; da Silva EM; Grabenstetter A; Jalali S; Gazzo AM; Dopeso H; Marra A; Brown DN; Ross DS; Mandelker D; Razavi P; Chandarlapaty S; Wen HY; Brogi E; Zhang H; Weigelt B; Pareja F; Reis-Filho JS
Mod Pathol; 2024 Feb; 37(2):100375. PubMed ID: 37925055
[TBL] [Abstract][Full Text] [Related]
18. Invasive lobular breast cancer and its variants: how special are they for systemic therapy decisions?
Guiu S; Wolfer A; Jacot W; Fumoleau P; Romieu G; Bonnetain F; Fiche M
Crit Rev Oncol Hematol; 2014 Dec; 92(3):235-57. PubMed ID: 25129506
[TBL] [Abstract][Full Text] [Related]
19. Characterization of Stromal Tumor-infiltrating Lymphocytes and Genomic Alterations in Metastatic Lobular Breast Cancer.
Richard F; Majjaj S; Venet D; Rothé F; Pingitore J; Boeckx B; Marchio C; Clatot F; Bertucci F; Mariani O; Galant C; Eynden GVD; Salgado R; Biganzoli E; Lambrechts D; Vincent-Salomon A; Pruneri G; Larsimont D; Sotiriou C; Desmedt C
Clin Cancer Res; 2020 Dec; 26(23):6254-6265. PubMed ID: 32943456
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant chemotherapy in patients with invasive lobular carcinoma and use of the 21-gene recurrence score: A National Cancer Database analysis.
Weiser R; Polychronopoulou E; Hatch SS; Haque W; Ghani HA; He J; Kuo YF; Gradishar WJ; Klimberg VS
Cancer; 2022 May; 128(9):1738-1747. PubMed ID: 35137951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
